Tenet Healthcare $THC Surges on 45% Q2 EPS Beat

Tenet Healthcare $THC jumped sharply on Friday after posting a blockbuster second quarter that beat Wall Street estimates by a wide margin and came with a major hike to full-year 2026 guidance. The stock was up roughly 17% to 23% in after-hours and early trading reports following Thursday night’s release, as investors reacted to stronger profitability, rising revenue, and improved outlook language.

What Happened

Tenet reported adjusted EPS of $6.12, crushing the $4.23 consensus estimate by about 45%, while revenue rose 6.8% year over year to $5.63 billion, above expectations of about $5.43 billion to $5.44 billion. The company also said adjusted diluted EPS increased 52.2% from $4.02 a year earlier, with net operating revenue growth driven by same-facility performance, acquisitions, and disciplined expense control.

Management paired the beat with a meaningfully stronger 2026 outlook. Tenet raised its full-year adjusted EBITDA guidance to $4.83 billion to $5.03 billion, up $295 million at the midpoint, and lifted adjusted free cash flow guidance to $2.725 billion to $3.025 billion. The company also increased its revenue outlook to $21.9 billion to $22.5 billion and said the quarter reflected strong hospital volumes, higher-acuity services, and ambulatory surgery growth.

Adjusted EPS: $6.12 vs. $4.23 consensus
Revenue: $5.63 billion, up 6.8% year over year
FY 2026 adjusted EBITDA guidance: $4.83 billion to $5.03 billion
FY 2026 adjusted free cash flow guidance: $2.725 billion to $3.025 billion

Analyst Take

The market reaction fits a classic high-quality beat-and-raise setup. Tenet is showing that demand for hospital services remains resilient, while margin gains suggest the operator is getting leverage from volume growth and cost discipline rather than relying on one-off benefits.

For traders, the size of the EPS beat matters as much as the guide raise. A result that came in roughly 45% above consensus is the kind of surprise that can force revisions higher across the Street, especially when management backs it up with stronger EBITDA, cash flow, and revenue targets. That combination tends to support momentum in the stock and can also lift sentiment toward the broader healthcare and hospital-services group.

What to Watch

Investors will now focus on whether Tenet can sustain hospital volume strength and keep margins elevated in the second half of 2026. The key question is whether the current pace of same-facility revenue growth and higher-acuity case mix continues without a meaningful slowdown in payer mix or reimbursement pressure.

Also important: how the new guidance holds up against subsequent quarterly results. If Tenet keeps delivering above plan, the raised outlook could reset valuation expectations for the rest of the year. If growth normalizes faster than expected, some of Friday’s move could fade.

Volume trends: hospital occupancy, same-facility growth, and higher-acuity procedures
Margins: whether expense control continues to offset mix pressure
Guide credibility: execution against the new revenue, EBITDA, EPS, and free cash flow ranges
Sector read-through: whether the quarter reinforces bullish positioning in healthcare services

Tenet Healthcare $THC Surges on 45% Q2 EPS Beat